PortfoliosLab logo
Bolt Biotherapeutics, Inc. (BOLT)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US0977021049

CUSIP

097702104

IPO Date

Feb 5, 2021

Highlights

Market Cap

$14.19M

EPS (TTM)

-$1.65

Total Revenue (TTM)

$2.42M

Gross Profit (TTM)

-$13.02M

EBITDA (TTM)

-$49.82M

Year Range

$0.30 - $1.04

Target Price

$1.00

Short %

0.69%

Short Ratio

2.03

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Popular comparisons:
BOLT vs. SCHG
Popular comparisons:

Performance

Performance Chart


Loading data...

Returns By Period

Bolt Biotherapeutics, Inc. (BOLT) returned -30.85% year-to-date (YTD) and -70.63% over the past 12 months.


BOLT

YTD

-30.85%

1M

14.30%

6M

-41.82%

1Y

-70.63%

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-0.64%

1M

8.97%

6M

-2.62%

1Y

11.90%

5Y*

15.76%

10Y*

10.69%

*Annualized

Monthly Returns

The table below presents the monthly returns of BOLT, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-8.43%-3.16%-15.70%-11.18%4.14%-30.85%
2024-9.82%12.87%22.81%-21.07%-31.52%-0.89%-0.15%-9.52%-4.37%-2.05%0.93%-16.47%-52.22%
202313.08%9.52%-13.66%13.67%8.86%-25.58%5.47%-18.52%-5.45%-5.77%-12.96%31.30%-13.85%
2022-21.63%-9.11%-21.49%-43.07%8.97%20.00%6.37%-17.05%-17.78%-6.08%6.47%-12.16%-73.47%
2021-16.95%23.26%-32.06%-21.69%-11.71%-27.88%59.28%-28.77%3.48%-29.18%-47.14%-84.76%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of BOLT is 7, meaning it’s performing worse than 93% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of BOLT is 77
Overall Rank
The Sharpe Ratio Rank of BOLT is 22
Sharpe Ratio Rank
The Sortino Ratio Rank of BOLT is 44
Sortino Ratio Rank
The Omega Ratio Rank of BOLT is 33
Omega Ratio Rank
The Calmar Ratio Rank of BOLT is 99
Calmar Ratio Rank
The Martin Ratio Rank of BOLT is 1717
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Bolt Biotherapeutics, Inc. (BOLT) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Bolt Biotherapeutics, Inc. Sharpe ratios as of May 13, 2025 (values are recalculated daily):

  • 1-Year: -1.14
  • All Time: -0.86

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Bolt Biotherapeutics, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History


Bolt Biotherapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Bolt Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bolt Biotherapeutics, Inc. was 99.22%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Bolt Biotherapeutics, Inc. drawdown is 99.07%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.22%Mar 18, 20211020Apr 8, 2025
-22.7%Feb 11, 202111Feb 26, 20217Mar 9, 202118
-0.51%Mar 15, 20211Mar 15, 20211Mar 16, 20212
-0.2%Mar 10, 20211Mar 10, 20211Mar 11, 20212

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bolt Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Bolt Biotherapeutics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 19.4% positive surprise.


-15.00-10.00-5.000.0020212022202320242025
-0.29
-0.36
Actual
Estimate

Valuation

The Valuation section provides an overview of how Bolt Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BOLT relative to other companies in the Biotechnology industry. Currently, BOLT has a P/S ratio of 1.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BOLT in comparison with other companies in the Biotechnology industry. Currently, BOLT has a P/B value of 0.2. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items